Psychosis with paranoid delusions after a therapeutic dose of mefloquine: A case report

Malaria Journal

Volumn 5, Issue , 2006, Pages

  Tran, Tuan M ^a   Browning, Joseph ^a   Dell, Mary L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; HALOPERIDOL; LEVOFLOXACIN; LISINOPRIL; MEFLOQUINE; METFORMIN; METOPROLOL; QUETIAPINE; ROSIGLITAZONE; ZOLPIDEM;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REGIMEN; ELECTROENCEPHALOGRAM; EMERGENCY WARD; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERTENSION; LABORATORY TEST; MALARIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARANOIA; PHYSICAL EXAMINATION; PSYCHOSIS; SUICIDAL BEHAVIOR; URINALYSIS;

ADULT; ANTIMALARIALS; HUMANS; MALARIA, FALCIPARUM; MALE; MEFLOQUINE; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 33748583178     PISSN: 14752875     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-5-74     Document Type: Article

References (29)

1. Karbwang J, White NJ: Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet 1990, 19:264-279.
2. CDC: Health Information for International Travel 2005-2006 Atlanta: US Department of Health and Human Services, Public Health Service; 2005.
3. Hughes C, Tucker R, Bannister B, Bradley DJ: Malaria prophylaxis for long-term travellers. Commun Dis Public Health 2003, 6:200-208.
4. Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD, Toovey S, Knobloch J, Nothdurft HD, Shaw D, et al.: Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 2001, 33:1015-1021.
5. Schlagenhauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwartz E, Herold M, Krebs B, Veit O, Allwinn R, Steffen R: Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. Bmj 2003, 327:1078.
6. Lancaster DL, Adio RA, Tai KK, Simooya OO, Broadhead GD, Tucker GT, Lennard MS: Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs. J Pharm Pharmacol 1990, 42:267-271.
7. Ball P, Mandell L, Niki Y, Tillotson G: Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf 1999, 21:407-421.
8. Barbee JG, Mancuso DM, Freed CR, Todorov AA: Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. Am J Psychiatry 1992, 149:506-510.
9. Bodkin JA: Emerging uses for high-potency benzodiazepines in psychotic disorders. J Clin Psychiatry 1990, 51(Suppl):41-46. discussion 50-43
10. Jonas JM, Cohon MS: A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature. J Clin Psychiatry 1993, 54(Suppl):25-45. discussion 46-28
11. Markowitz JS, Brewerton TD: Zolpidem-induced psychosis. Ann Clin Psychiatry 1996, 8:89-91.
12. WHO: Review of central nervous system adverse events related to the antimalaria drug, mefloquine (1985-1990). In Book Review of central nervous system adverse events related to the antimalaria drug, mefloquine (1985-1990) City: Malaria Control Unit, Division of Control of Tropical Diseases, WHO and Drug Safety Unit, F. Hoffman-La-Roche.
13. Lobel HO, Miani M, Eng T, Bernard KW, Hightower AW, Campbell CC: Long-term malaria prophylaxis with weekly mefloquine. Lancet 1993, 341:848-851.
14. Meier CR, Wilcock K, Jick SS: The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials. Drug Saf 2004, 27:203-213.
15. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ, et al.: Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004, 364:438-447.
16. Rendi-Wagner P, Noedl H, Wernsdorfer WH, Wiedermann G, Mikolasek A, Kollaritsch H: Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults. Acta Trop 2002, 81:167-173.
17. Weinke T, Trautmann M, Held T, Weber G, Eichenlaub D, Fleischer K, Kern W, Pohle HD: Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 1991, 45:86-91.
18. ter Kuile FO, Nosten F, Thieren M, Luxemburger C, Edstein MD, Chongsuphajaisiddhi T, Phaipun L, Webster HK, White NJ: High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J Infect Dis 1992, 166:1393-1400.
19. Smithuis FM, van Woensel JB, Nordlander E, Vantha WS, ter Kuile FO: Comparison of two mefloquine regimens for treatment of Plasmodium falciparum malaria on the northeastern Thai-Cambodian border. Antimicrob Agents Chemother 1993, 37:1977-1981.
20. Taylor WR, White NJ: Antimalarial drug toxicity: a review. Drug Saf 2004, 27:25-61.
21. ter Kuile FO, Luxemburger C, Nosten F, Thwai KL, Chongsuphajaisiddhi T, White NJ: Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 1995, 89:660-664.
22. Lobel HO, Coyne PE, Rosenthal PJ: Drug overdoses with antimalarial agents: prescribing and dispensing errors. Jama 1998, 280:1483.
23. Schwartz E, Potasman I, Rotenberg M, Almog S, Sadetzki S: Serious adverse events of mefloquine in relation to blood level and gender. Am J Trop Med Hyg 2001, 65:189-192.
24. Dow GS, Hudson TH, Vahey M, Koenig ML: The acute neurotoxicity of mefloquine may be mediated through a disruption of calcium homeostasis and ER function in vitro. Malar J 2003, 2:14.
25. Cruikshank SJ, Hopperstad M, Younger M, Connors BW, Spray DC, Srinivas M: Potent block of Cx36 and Cx50 gap junction channels by mefloquine. Proc Natl Acad Sci USA 2004, 101:12364-12369.
26. Croft AM, Herxheimer A: Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement? BMC Public Health 2002, 2:6.
27. Piening RB, Young SA: Mefloquine-induced psychosis. Ann Emerg Med 1996, 27:792-793.
28. Dietz A, Frolich L: Mefloquine-induced paranoid psychosis and subsequent major depression in a 25-year-old student. Pharmacopsychiatry 2002, 35:200-202.
29. Kukoyi O, Carney CP: Curses, madness, and mefloquine. Psychosomatics 2003, 44:339-341.